{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T04:50:39Z","timestamp":1767761439104,"version":"3.48.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-025-12214-8","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:43:42Z","timestamp":1767714222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Are we ready for amyloid-related imaging abnormalities (ARIA) monitoring? A European survey among neuroradiologists and neurologists by the ESNR\/EAN Working Group"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0509-0562","authenticated-orcid":false,"given":"Tiago Gil","family":"Oliveira","sequence":"first","affiliation":[]},{"given":"Meike W.","family":"Vernooij","sequence":"additional","affiliation":[]},{"given":"Giovanni B.","family":"Frisoni","sequence":"additional","affiliation":[]},{"given":"Roland","family":"Wiest","sequence":"additional","affiliation":[]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"12214_CR1","doi-asserted-by":"publisher","unstructured":"(2024) 2024 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 20:3708\u20133821. https:\/\/doi.org\/10.1002\/alz.13809","DOI":"10.1002\/alz.13809"},{"key":"12214_CR2","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/j.neuron.2022.03.034","volume":"110","author":"WJ Lee","year":"2022","unstructured":"Lee WJ, Brown JA, Kim HR et al (2022) Regional A\u03b2-tau interactions promote onset and acceleration of Alzheimer\u2019s disease tau spreading. Neuron 110:1932\u20131943.e5. https:\/\/doi.org\/10.1016\/j.neuron.2022.03.034","journal-title":"Neuron"},{"key":"12214_CR3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41380-020-0721-9","volume":"26","author":"H Zetterberg","year":"2021","unstructured":"Zetterberg H, Bendlin BB (2021) Biomarkers for Alzheimer\u2019s disease\u2014preparing for a new era of disease-modifying therapies. Mol Psychiatry 26:296\u2013308. https:\/\/doi.org\/10.1038\/s41380-020-0721-9","journal-title":"Mol Psychiatry"},{"key":"12214_CR4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330:512\u2013527. https:\/\/doi.org\/10.1001\/jama.2023.13239","journal-title":"JAMA"},{"key":"12214_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Dyck","year":"2023","unstructured":"Dyck CH, van, Swanson CJ, Aisen P et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"12214_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F et al (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis 9:197\u2013210. https:\/\/doi.org\/10.14283\/jpad.2022.30","journal-title":"J Prev Alzheimers Dis"},{"key":"12214_CR7","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, Elhage A, Cho M et al (2023) Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain 146:4414\u20134424. https:\/\/doi.org\/10.1093\/brain\/awad188","journal-title":"Brain"},{"key":"12214_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3174\/ajnr.A8469","volume":"46","author":"PM Cogswell","year":"2025","unstructured":"Cogswell PM, Andrews TJ, Barakos JA et al (2025) Alzheimer disease anti-amyloid immunotherapies: imaging recommendations and practice considerations for monitoring of amyloid-related imaging abnormalities. AJNR Am J Neuroradiol 46:24\u201332. https:\/\/doi.org\/10.3174\/ajnr.A8469","journal-title":"AJNR Am J Neuroradiol"},{"key":"12214_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","volume":"79","author":"M Filippi","year":"2022","unstructured":"Filippi M, Cecchetti G, Spinelli EG et al (2022) Amyloid-related imaging abnormalities and \u03b2-amyloid\u2013targeting antibodies: a systematic review. JAMA Neurol 79:291\u2013304. https:\/\/doi.org\/10.1001\/jamaneurol.2021.5205","journal-title":"JAMA Neurol"},{"key":"12214_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F et al (2022) Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol 79:13\u201321. https:\/\/doi.org\/10.1001\/jamaneurol.2021.4161","journal-title":"JAMA Neurol"},{"key":"12214_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/jamaneurol.2024.3937","volume":"82","author":"S Salloway","year":"2025","unstructured":"Salloway S, Wojtowicz J, Voyle N et al (2025) Amyloid-related imaging abnormalities (ARIA) in clinical trials of gantenerumab in early Alzheimer disease. JAMA Neurol 82:19. https:\/\/doi.org\/10.1001\/jamaneurol.2024.3937","journal-title":"JAMA Neurol"},{"key":"12214_CR12","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMc2215148","volume":"388","author":"NJ Reish","year":"2023","unstructured":"Reish NJ, Jamshidi P, Stamm B et al (2023) Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke. N Engl J Med 388:478\u2013479. https:\/\/doi.org\/10.1056\/NEJMc2215148","journal-title":"N Engl J Med"},{"key":"12214_CR13","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1212\/01.wnl.0000307750.41970.d9","volume":"70","author":"MW Vernooij","year":"2008","unstructured":"Vernooij MW, van der Lugt A, Ikram MA et al (2008) Prevalence and risk factors of cerebral microbleeds. Neurology 70:1208\u20131214. https:\/\/doi.org\/10.1212\/01.wnl.0000307750.41970.d9","journal-title":"Neurology"},{"key":"12214_CR14","doi-asserted-by":"publisher","first-page":"E19","DOI":"10.3174\/ajnr.A7586","volume":"43","author":"PM Cogswell","year":"2022","unstructured":"Cogswell PM, Barakos JA, Barkhof F et al (2022) Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice. AJNR Am J Neuroradiol 43:E19\u2013E35. https:\/\/doi.org\/10.3174\/ajnr.A7586","journal-title":"AJNR Am J Neuroradiol"},{"key":"12214_CR15","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD et al (2023) Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis 10:362\u2013377. https:\/\/doi.org\/10.14283\/jpad.2023.30","journal-title":"J Prev Alzheimers Dis"},{"key":"12214_CR16","unstructured":"Commission authorises medicine for treatment of early Alzheimer\u2019s disease. Available via https:\/\/ec.europa.eu\/newsroom\/sante\/items\/879055\/en. Accessed 20 Apr 2025"},{"key":"12214_CR17","unstructured":"European Medicines Agency (2025) European Medicines Agency issues a positive opinion regarding kinsula\/donanemab. Available via https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-kisunla_en.pdf. Accessed 17 Aug 2025"},{"key":"12214_CR18","doi-asserted-by":"publisher","first-page":"100150","DOI":"10.1016\/j.tjpad.2025.100150","volume":"12","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Selkoe DJ, Schindler SE et al (2025) Donanemab: appropriate use recommendations. J Prev Alzheimers Dis 12:100150. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100150","journal-title":"J Prev Alzheimers Dis"},{"key":"12214_CR19","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3174\/ajnr.A1355","volume":"30","author":"RNK Nandigam","year":"2009","unstructured":"Nandigam RNK, Viswanathan A, Delgado P et al (2009) MR imaging detection of cerebral microbleeds: effect of susceptibility-weighted imaging, section thickness, and field strength. AJNR Am J Neuroradiol 30:338\u2013343. https:\/\/doi.org\/10.3174\/ajnr.A1355","journal-title":"AJNR Am J Neuroradiol"},{"key":"12214_CR20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR, Black SE et al (2011) Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement 7:367\u2013385. https:\/\/doi.org\/10.1016\/j.jalz.2011.05.2351","journal-title":"Alzheimers Dement"},{"key":"12214_CR21","doi-asserted-by":"publisher","first-page":"e2355800","DOI":"10.1001\/jamanetworkopen.2023.55800","volume":"7","author":"DM Sima","year":"2024","unstructured":"Sima DM, Phan TV, Van Eyndhoven S et al (2024) Artificial intelligence assistive software tool for automated detection and quantification of amyloid-related imaging abnormalities. JAMA Netw Open 7:e2355800. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.55800","journal-title":"JAMA Netw Open"},{"key":"12214_CR22","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1002\/mrm.25347","volume":"73","author":"B Bilgic","year":"2015","unstructured":"Bilgic B, Gagoski BA, Cauley SF et al (2015) Wave-CAIPI for highly accelerated 3D imaging. Magn Reson Med 73:2152\u20132162. https:\/\/doi.org\/10.1002\/mrm.25347","journal-title":"Magn Reson Med"},{"key":"12214_CR23","doi-asserted-by":"publisher","first-page":"7025","DOI":"10.1007\/s00330-023-09701-1","volume":"33","author":"J Hodel","year":"2023","unstructured":"Hodel J, Vernooij MW, Beyer MK et al (2023) Multiple sclerosis imaging in clinical practice: a European-wide survey of 428 centers and conclusions by the ESNR Working Group. Eur Radiol 33:7025\u20137033. https:\/\/doi.org\/10.1007\/s00330-023-09701-1","journal-title":"Eur Radiol"},{"key":"12214_CR24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00234-023-03255-1","volume":"66","author":"S Gerevini","year":"2024","unstructured":"Gerevini S, Cristiano L, D\u2019Anna G et al (2024) Neuromuscular imaging in clinical practice: an ESNR survey of 30 centers. Neuroradiology 66:179\u2013186. https:\/\/doi.org\/10.1007\/s00234-023-03255-1","journal-title":"Neuroradiology"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-12214-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-12214-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-12214-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T04:41:14Z","timestamp":1767760874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-12214-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":24,"alternative-id":["12214"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-12214-8","relation":{},"ISSN":["1432-1084"],"issn-type":[{"type":"electronic","value":"1432-1084"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is T.G.O.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare relationships with the following companies: T.G.O. has been a consultant for Sonae and Guidepoint, has received fees as a speaker from Eisai and conference fees covered from Roche and Lilly. M.V. has received fees as a speaker from Eisai. Advisory board member for the Dutch Alzheimer Foundation (Alzheimer Nederland). G.B.F. has received consulting fees from: Biogen, Diadem, Roche; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from: Biogen, Roche, Novo Nordisk, and GE HealthCare (all of these through his institution). R.W.: Advisory board member for EISAI, Lilly, and Bayer. R.W. has received speaker honorarium from Lilly and Bayer. F.B.: Steering committee or Data Safety Monitoring Board member for Biogen, Merck, Eisai, and Prothena. Advisory board member for Combinostics, Scottish Brain Sciences, Alzheimer Europe. Consultant for Roche, Celltrion, Rewind Therapeutics, Merck, and Bracco. Research agreements with ADDI, Merck, Biogen, GE Healthcare, and Roche. Co-founder and shareholder of Queen Square Analytics LTD.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was not required for this study because the results presented were based on a voluntary online survey.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The questionnaire was reviewed and approved by the ESNR and EAN scientific panels.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}